Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia

December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discontinue active treatment was comparable to that of patients randomized to continue IMBRUVICA® monotherapy (95.3 percent vs. 100 percent, respectively [p=0.1475]).[1] These data, presented by the Janssen Pharmaceutical Companies of Johnson &Johnson, show the synergistic effect of these two therapies and their combined potential to clear disease from peripheral blood (PB) and bone marrow (BM).1 “These data demonstrate the potential of this all-oral, once-daily, chemotherapy-free combination regimen in first-line treatment of CLL,” said William Wierda, M.D., Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center and principal study investigator. “Once-daily treatment with ibrutinib remains the established standard of care in CLL; the latest results from the CAPTIVATE study underscore that the mechan...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Acute Leukemia | Allergy & Immunology | Anemia | Arrhythmia | Atrial Fibrillation | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Child Development | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Education | Environmental Health | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Headache | Health Management | Heart | Hematology | Hormones | Hypertension | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Leukemia | Lymphoma | Macroglobulinemia | Melanoma | Migraine | Neurology | Neuroscience | Neurosurgery | Nonmelanoma Skin Cancer | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Pregnancy | Primary CNS Lymphoma | Profits and Losses | Pulmonary Hypertension | Rituxan | Science | Skin | Skin Cancer | Skin Graft | Study | Texas University | Thrombocytopenia | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Waldenstrom's Macroglobulinemia | Warnings | Women